Stanford Health Care explains progesterone’s accompanying role within some estrogen treatment plans. That is more specific than a general promise of hormone care. Yet it still leaves a second question unanswered: which medicine, by which route, would actually be prescribed?
This review, dated September 29, 2026, examines Stanford’s menopause service and treatment description. The pages verify clinical care but do not name an oral progesterone product or a dispensing pharmacy. Their broad route list needs to remain separate from the evidence for a particular capsule.
In this article
The service addresses menopause through several paths
Stanford’s menopause overview describes evaluation and treatment, with hormonal and nonhormonal options. It points to in-person care and video visits. Those are service features, not a guarantee of remote eligibility from any location or a promise that a medicine will be prescribed after a particular visit.
The UCLA review provides a useful comparison because its comprehensive program explicitly includes sleep and other health domains. Both services describe a wider assessment than a capsule request. The appropriate comparison is the published clinical scope and access pathway. Neither page establishes a personal outcome, complete treatment price or one product that every patient receives.
The accompanying role is described, but remains clinical
Stanford’s treatment page explains that the presence or absence of a uterus affects discussion of estrogen alone versus estrogen with progesterone. This is a general treatment explanation. It does not allow a reader to determine a personal regimen from surgical history alone; the clinician still needs to assess the wider history and the proposed treatment.
Our oral progesterone purpose guide separates that role from assumptions about the capsule itself. The Stanford page does not name Prometrium as its standard choice. It also does not provide an individual prescription, tell a patient to add a medicine, or establish that every estrogen product has the same accompanying requirements.
A route list does not distribute itself across every hormone
The same Stanford treatment page lists several hormone-delivery formats, including pills and products used through the skin or vagina. It does not provide a table matching each hormone to each route. The actual treatment description therefore cannot establish that a progesterone cream, an oral capsule and another preparation offer equivalent effects or protection.
This is a particular reason to keep the names of medicines separate within a plan. “My hormone treatment” can conceal which product performs which role. A clinician’s written explanation would need the exact formulation and route for each component. The broad page is useful background, but it cannot substitute for route-specific evidence or justify a switch between preparations.
The oral reference has its own limits
The Prometrium label documents oral micronized progesterone, including its specified use with estrogen after menopause. It does not validate every broad benefit discussed on a menopause webpage. In particular, a general discussion of long-term health should not be converted into a claim that this capsule prevents cardiovascular disease; the label does not establish that preventive benefit.
The Prometrium review keeps the product’s evidence and warnings together. FDA also explains that compounded medicines have a different approval status. These distinctions do not establish that Stanford supplies a compounded product. They identify what remains to be clarified if a particular formulation is proposed in care.
A precise route still does not identify every ingredient
Even knowing that a medicine is oral does not provide its full ingredient record. Prometrium’s label lists peanut oil and includes a contraindication for peanut allergy. That information is specific to the documented product, not a statement about every possible oral progesterone preparation or about what Stanford will prescribe.
Our capsule excipients guide explains the remaining identification step. A clinician’s assessment of allergy history and a pharmacist’s confirmation of the actual supplied formulation address different parts of the question. The service overview cannot establish either conclusion for a reader, and an ingredient concern should not be treated as permission to replace one formulation with another without professional assessment.
Access and financial questions remain attached to the encounter
Stanford describes care through its clinical services, including video options, but the reviewed pages do not publish a universal oral progesterone package. The menopause overview leaves the complete encounter cost, medicine price, coverage and dispensing arrangements unresolved. A video option does not turn a regional service into a nationwide capsule subscription.
The University of Utah review supplies a different practical comparison, with more detail about the initial consultation. For Stanford, useful confirmation would identify the particular clinic, appointment format and responsibilities for any later prescription. It would not combine unrelated website services into one assumed price or promise that all follow-up is included.
The rationale and the cautions should travel together
A medicine’s purpose should remain understandable after the visit, alongside the product information and the person responsible for later concerns. Prometrium’s current patient label includes dizziness and drowsiness cautions as well as serious warnings and contraindications. A broad description of hormone benefits does not erase that context.
The drowsiness guide and follow-up guide address questions without prescribing a schedule. Stanford’s public information provides a clear starting explanation of progesterone’s accompanying role. The fair limit is equally clear: this review has not confirmed the exact oral medicine, its ingredients, personal suitability or an individual follow-up plan, and offers no instruction to start, stop or alter treatment.
Sources for this article
Source type matters. A provider page describes an offer; an exact product label describes that medicine.
- Stanford Health Care — MenopauseOfficial health-system clinical service or location information; individual access, oral product and full price unconfirmed. · Checked 2026-09-29
- Stanford Health Care — Menopause TreatmentsOfficial health-system clinical service or location information; individual access, oral product and full price unconfirmed. · Checked 2026-09-29
- DailyMed — Prometrium progesterone capsule, Acertis Pharmaceuticals LLCCurrent exact oral Prometrium DailyMed label, updated July 23, 2026; patient leaflet revision February 2026. Does not establish provider supply. · Checked 2026-09-29
- FDA — Understanding the Risks of Compounded DrugsFederal primary drug-label or regulatory information; applies only within the stated product and regulatory scope. · Checked 2026-09-29